5/7/2013

Concert Pharmaceuticals granted Celgene the right to use its deuterated chemical entity technology to develop new deuterium-modified small compounds for cancer and inflammation. Concert will get an upfront payment and more than $300 million in possible milestone fees for each program selected for development, plus sales royalties.

Related Summaries